# Phase 5.2F.1 — Introduction Word Count Closure Report

> **Document Type:** MANUSCRIPT EDITORIAL COMPLIANCE REPORT  
> **Evaluation Subject:** Word Count Reconciliation of `research/manuscript/PHASE5_2B_INTRODUCTION.md`  
> **Pre-Closure Word Count:** 1,330 words  
> **Post-Closure Word Count:** 1,276 words  
> **Target Requirement:** 900 to 1,300 words (Target: ~1,270 to 1,290 words)  
> **Governing Baselines:**  
>   - `research/manuscript/PHASE5_2F_CORRECTION_REPORT.md`  
>   - `research/manuscript/PHASE5_2E_CROSS_SECTION_AUDIT.md`  
>   - `research/manifest/phase2c_primary.json` (SHA256: `39eb60de0e60dea8a76f2290912905b197fb1a04b738f72b0493bcdab2e0eb96`)  
> **Execution Date:** 2026-10-09  
> **Status:** PASSED AND CERTIFIED (1,276 WORDS, ZERO DISCLOSURE LOSS)  

---

## 1. Executive Summary & Verification Verdict

```
═══════════════════════════════════════════════════════════════════════════════════
                 PHASE 5.2F.1 INTRODUCTION WORD COUNT CLOSURE VERDICT               
═══════════════════════════════════════════════════════════════════════════════════

  OVERALL VERDICT:                  PASS — FULLY COMPLIANT
  INTRODUCTION BODY WORD COUNT:     1,276 WORDS (TARGET: 1,270–1,290; CEILING: 1,300)
  PRE-CLOSURE BODY WORD COUNT:      1,330 WORDS (-54 WORDS REDUCED)
  INCORPORATION BIAS DISCLOSURE:    100% PRESERVED (`comparison_status == "EXACT_AGREEMENT"`)
  UNREPRESENTED CLASSES DISCLOSURE: 100% PRESERVED (C05, C07, C08, C10 n=0 DISCLOSED)
  SCIENTIFIC CITATIONS STATUS:      100% PRESERVED (ALL 15 REFERENCES RETAINED)
  DATASET HASH INTEGRITY:           100% BIT-FOR-BIT IDENTICAL (PRIMARY & TEST HASHES MATCH)
  FILE MODIFICATION ISOLATION:      STRICT (ONLY PHASE5_2B_INTRODUCTION.md EDITED)

═══════════════════════════════════════════════════════════════════════════════════
```

Following the incorporation of the mandatory curation bias and class representation disclosures in Phase 5.2F, the body text of the Introduction expanded to 1,330 words, slightly exceeding the 1,300-word ceiling. Under Phase 5.2F.1, redundant and stylistic phrasing across early sections (§1–§3) was streamlined while strictly preserving all scientific facts, qualifications, literature citations, and the newly added CP2.2 bias disclosures. The resulting Introduction body text contains exactly **1,276 words**, achieving complete compliance with the 900 to 1,300-word standard.

---

## 2. Documented Word Count Methodology

To ensure absolute reproducibility and prevent ambiguities arising from different word-counting utilities, the word count was verified using an explicit, deterministic counting script:

```powershell
$content = Get-Content "research/manuscript/PHASE5_2B_INTRODUCTION.md" -Raw

# 1. Isolate the Introduction body text (from '# Introduction' to the start of '## References')
if ($content -match "(?s)# Introduction\r?\n\r?\n(.*?)\r?\n---\r?\n\r?\n## References") {
    $introBody = $matches[1]

    # 2. Exclude section markdown header lines ("## 1. HBB...", "## 2. Standardized...", etc.)
    $cleaned = $introBody -replace "## \d+\..*?\r?\n", ""

    # 3. Tokenize by whitespace delimiter and filter empty tokens
    $words = ($cleaned -split "\s+") | Where-Object { $_ -ne "" }

    Write-Output "Verified Introduction body word count: $($words.Count)"
}
```

### Breakdown of Words by Paragraph:
| Section & Paragraph | Topic | Pre-Closure Words | Post-Closure Words | Change ($\Delta$) | Action Taken |
|---|---|:---:|:---:|:---:|---|
| **§1. Para 1** | *HBB* Biology & Hemoglobinopathies | 149 | **139** | -10 | Condensed erythrocyte oxygen carrier description and variant mechanism clause; preserved all 4 citations. |
| **§2. Para 2** | HGVS Syntax & Legacy Codon Offsets | 160 | **150** | -10 | Removed redundant wording describing reference anchoring and mature polypeptide numbering; preserved both citations. |
| **§3. Para 3** | Reference Sequence Models & MANE Select | 130 | **114** | -16 | Streamlined MANE Select initiative description and cDNA coordinate contrast; preserved both citations. |
| **§4. Para 4** | Deterministic Consequence vs Pathogenicity | 169 | **151** | -18 | Tightened tool list description and ML predictor contrast; preserved both citations. |
| **§4. Para 5** | Consequence vs ACMG Clinical Pathogenicity | 177 | **177** | 0 | Unchanged; critical conceptual distinction preserved intact. |
| **§5. Para 6** | External ClinVar Reference Context | 155 | **155** | 0 | Unchanged; repository artifact explanation preserved intact. |
| **§6. Para 7** | Motivation & Research Gap | 149 | **149** | 0 | Unchanged; benchmarking justification preserved intact. |
| **§7. Para 8** | Study Objective, Endpoints & Limitations | 147 | **147** | 0 | Unchanged; primary endpoint, secondary endpoint, and robustness cohort preserved. |
| **§7. Para 9** | CP2.2 Incorporation Bias & Absent Classes | 94 | **94** | 0 | Unchanged; explicit disclosure of CP2.2 `EXACT_AGREEMENT` filter and 4 absent classes. |
| **TOTAL** | **Complete Introduction Body Text** | **1,330** | **1,276** | **-54** | **Target Met: 1,276 words (1,270–1,290 target)** |

---

## 3. Preservation Verification of Required Scientific Disclosures

Every required scientific disclosure was explicitly re-checked in the final text of `research/manuscript/PHASE5_2B_INTRODUCTION.md`:

### A. CP2.2 Curation Filter (`comparison_status == "EXACT_AGREEMENT"`)
- **Verification Query:** `Select-String -Path "research/manuscript/PHASE5_2B_INTRODUCTION.md" -Pattern "EXACT_AGREEMENT"`
- **Verified Text (Section 7, line 37):**
  > *"Crucially, during CP2.2 curation, admission to the proposed primary cohort required deterministic engine agreement (`comparison_status == "EXACT_AGREEMENT"`)."*
- **Status:** **CONFIRMED PRESENT AND UNALTERED.**

### B. Incorporation / Verification Bias Explanation
- **Verification Query:** `Select-String -Path "research/manuscript/PHASE5_2B_INTRODUCTION.md" -Pattern "incorporation or verification bias"`
- **Verified Text (Section 7, line 37):**
  > *"The primary cohort was therefore not selected independently of engine agreement, creating incorporation or verification bias. This selection mechanism limits interpretation of the observed concordance and prevents treating it as an unbiased estimate of performance on unseen \*HBB\* variants."*
- **Status:** **CONFIRMED PRESENT AND UNALTERED.**

### C. Unrepresented Biological Mutation Classes ($n = 0$)
- **Verification Query:** `Select-String -Path "research/manuscript/PHASE5_2B_INTRODUCTION.md" -Pattern "C05 in-frame indels"`
- **Verified Text (Section 7, line 37):**
  > *"Furthermore, while the primary cohort represents seven biological classes, four classes (C05 in-frame indels, C07 in-frame duplications, C08 splice donor disruptions, and C10 5' UTR regulatory variants) had zero primary candidates and were not evaluated in this benchmark."*
- **Status:** **CONFIRMED PRESENT AND UNALTERED.**

### D. Study Objectives, Primary Endpoint, and Clinical Limitations
- **Verified Text (Section 7, line 35):**
  > *"The objective of this study was to evaluate deterministic molecular consequence prediction for \*HBB\* variants against a curated ClinVar-derived external annotation reference using a predefined and reproducible computational protocol... The primary evaluation endpoint was predefined as molecular consequence concordance between the runtime deterministic engine output and the curated external molecular annotation, with software regression baselines strictly isolated... This study explicitly evaluates computational concordance with curated external molecular annotations; it does not evaluate clinical significance, ACMG pathogenicity classification, diagnostic accuracy, or patient clinical outcomes."*
- **Status:** **CONFIRMED PRESENT AND UNALTERED.**

### E. Literature Citations Integrity
All 15 literature citations remain present and correctly cited in the text and reference section:
1. Thein (2013) [Cold Spring Harb Perspect Med]
2. Weatherall (2010) [Blood]
3. Taher et al. (2018) [Lancet]
4. Giardine et al. (2007) [Hum Mutat]
5. den Dunnen et al. (2016) [Hum Mutat]
6. O'Leary et al. (2016) [Nucleic Acids Res]
7. Morales et al. (2022) [Nature]
8. McLaren et al. (2016) [Genome Biol]
9. Wang et al. (2010) [Nucleic Acids Res]
10. Richards et al. (2015) [Genet Med]
11. Rehm et al. (2015) [N Engl J Med]
12. Landrum et al. (2018) [Nucleic Acids Res]
13. Harrison et al. (2017) [Genet Med]
14. Krusche et al. (2019) [Nat Biotechnol]
15. Stodden et al. (2016) [Science]
- **Status:** **100% PRESERVED.**

---

## 4. Cryptographic Baseline & Dataset Hash Verification

All frozen datasets and protocols remain bit-for-bit identical to their locked cryptographic baselines:

```
═══════════════════════════════════════════════════════════════════════════════════
                      CRYPTOGRAPHIC BASELINE INTEGRITY AUDIT                      
═══════════════════════════════════════════════════════════════════════════════════

  1. Primary Evaluation Dataset:
     - Path:              research/manifest/phase2c_primary.json
     - Recorded Size:     59,605 bytes (N = 55)
     - Computed SHA256:   39eb60de0e60dea8a76f2290912905b197fb1a04b738f72b0493bcdab2e0eb96
     - Expected SHA256:   39eb60de0e60dea8a76f2290912905b197fb1a04b738f72b0493bcdab2e0eb96
     - Verification:      MATCH (BIT-FOR-BIT IDENTICAL)

  2. Historical Test Manifest:
     - Path:              research/manifest/frozen_test.json
     - Recorded Size:     20,296 bytes (N = 20)
     - Computed SHA256:   2f6b88422b82d3f74c20f00985a34ffb5c1c78c311e4d8b584bc732cf5fc5994
     - Expected SHA256:   2f6b88422b82d3f74c20f00985a34ffb5c1c78c311e4d8b584bc732cf5fc5994
     - Verification:      MATCH (BIT-FOR-BIT IDENTICAL)

  3. Locked Benchmark Protocol:
     - Path:              research/protocol/PHASE2C_BENCHMARK_PROTOCOL.md
     - Recorded Size:     21,507 bytes
     - Computed SHA256:   e4bad0a095cdfa8112a649f3d8a0794cf0078d218611bb965020b100ba368969
     - Expected SHA256:   e4bad0a095cdfa8112a649f3d8a0794cf0078d218611bb965020b100ba368969
     - Verification:      MATCH (BIT-FOR-BIT IDENTICAL)

═══════════════════════════════════════════════════════════════════════════════════
```

---

## 5. Scope Isolation Confirmation

A full file audit confirms that:
- **`PHASE5_2A_TITLE_ABSTRACT.md`** was NOT modified in this phase.
- **`PHASE5_2C_METHODS.md`** was NOT modified in this phase.
- **`PHASE5_2D_RESULTS.md`** was NOT modified in this phase.
- Zero production code, comparison engines, benchmark runners, or benchmark summary JSON files were modified or re-run.
- Only `PHASE5_2B_INTRODUCTION.md` was edited to reconcile body word count.

---

## 6. Final Certification

Phase 5.2F.1 has achieved complete resolution:
- **Introduction Word Count:** Exactly **1,276 words** (within the 1,270 to 1,290 target, below the 1,300 ceiling).
- **Scientific Content:** 100% preserved, including CP2.2 incorporation bias, 4 unrepresented classes, primary/secondary endpoints, and clinical disclaimers.
- **Cryptographic Hashes:** Bit-for-bit identical to pre-registered baselines.

$$\mathbf{CERTIFICATION:\ PHASE\ 5.2F.1\ COMPLETE\ —\ READY\ FOR\ PHASE\ 5.3\ (DISCUSSION)}$$
